Furthermore, amivantamab (c-met/EGFR bsAb) has received FDA approval for three indications in EGFR-mutant NSCLC, including first-line in combination with chemotherapy for EGFR 20 insertion, first-line in combination with lazertinib, and postline in combination with chemotherapy for EGFR exon 19 deletion or L858R mutation [8–10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.